Details for Patent: 8,241,662

Summary for Patent: 8,241,662

Title:	Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy
Abstract:	The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
Inventor(s):	Ebert; Charles D. (Salt Lake City, UT), Sanders; Steven W. (Salt Lake City, UT)
Assignee:	Watson Laboratories, Inc. (Salt Lake City, UT)
Application Number:	11/645,076
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 8,241,662

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 8,241,662

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	488233
Australia	2001253782
Australia	2003287377
Australia	2003294239
Australia	2010200418
Australia	2012216593
Australia	5378201